Employers pick which drugs to cover and how much to chip in, using manufacturer pricing from Lilly and Novo, with Wegovy fills at retail pharmacies nationwide.
Recap by typeshit. Full story at FinancialContent.
Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
With 30% of covering employers weighing cuts, Wegovy and Zepbound users should check their plans now. Includes current self-pay prices and tips for appeals.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
West Pharmaceutical shares are up about 20% since CNBC flagged the valuation in August, and the latest earnings give it reasons to expect further gains.
A link to the FDA's list of bulk drug substances it says may carry significant safety risks in compounding, relevant to the peptide policy fight.
The analysis weighs whether Viking can become the third company, after Lilly and Novo Nordisk, to win approval for a GLP-1 weight loss drug.
Loading…